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Background: The purpose of this study was to determine the α/β ratio for normal liver with hepatitis by analyzing
the toxicity data from patients with unresectable hepatocellular carcinoma treated with helical tomotherapy.
Methods: Between March 2006 and February 2012, 98 patients were eligible for this study. 66 patients received
45–50 Gy in 4.5-5 Gy fractions (Group A) and 32 patients received 36–60 Gy in 2.5-3 Gy fractions (Group B).
Radiation-induced hepatic toxicity was defined as an increase of at least 2 points in the Child-Pugh score within
4 months of completing helical tomotherapy. We attempted to find the statistically significant parameters in the 2
groups using α/β ratios of 2, 4, 6, 8, or 10, and compared the estimated probability curves of each significant
parameter. We hypothesized that the α/β ratio associated with the best matches for the curves between the 2
groups would be equivalent to the α/β ratio for the normal liver.
Results: When using an α/β ratio of 2 or 4, different parameters were found to be statistically significant in a
multivariate analysis (Group A: VBED30 for α/β ratio = 2 and VBED25 for α/β ratio = 4, Group B: VBED25 for α/β ratio = 2
and VBED20 for α/β ratio = 4). When using an α/β ratio of 6, 8, or 10, VBED20 was found to be a statistically significant
parameter in both groups. Comparison of the estimated probability curve of each significant parameter between
the groups revealed that an α/β ratio of 8 resulted in the best matches.
Conclusions: We suggest that the α/β ratio of the normal liver with hepatitis is 8. We hope that previously
reported parameters and their values can be effectively used in different fractionation schemes by calculating the
biologically effective dose using an α/β ratio of 8.
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Radiation-induced hepatic toxicity (RIHT) is a serious
dose-limiting toxicity in patients with hepatocellular
carcinoma (HCC) receiving radiotherapy (RT) because
there is currently no effective treatment for RIHT, which
can ultimately cause liver failure [1]. Several studies have
shown that there are a number of predictive parameters* Correspondence: k41645@chol.com
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reproduction in any medium, provided the orfor RIHT, and these have helped to reduce hepatic toxicity
associated with the use of RT [2-11].
When treating patients with different fraction size
compared to those of previous studies, the expected
tumor response and hepatic toxicity could be estimated
by calculating the biologically effective dose (BED)
according to the linear-quadratic model. An α/β ratio of
10 is commonly used to calculate the BED delivered to
the tumor, but the BED for the normal liver could not
be calculated as its α/β ratio was unknown. In previous
studies on hepatic toxicity, an α/β ratio of 2–3 or 10 was. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fraction sizes and total doses of radiation [2,9,10].
In addition, the majority of patients with HCC have
hepatitis, unlike patients with metastatic liver tumors,
especially in eastern countries. In patients with HCC,
the tolerance of the normal liver to radiation was
considerably reduced [12]. Determining the α/β ratio
of the normal liver with hepatitis is important to improve
the tumor control and prevent the hepatic toxicity resulting
from the use of RT in HCC patients.
In this study, we attempt to determine the α/β ratio for
the normal liver with hepatitis by analyzing the hepatic
toxicity data from patients treated with 4.5-5 Gy per
fraction (Group A) and 2.5-3 Gy per fraction (Group B),
respectively, and comparing the 2 groups.
Methods
Patients
The inclusion criteria for this study were as follows: 1)
unresectable locally advanced HCC, 2) prior treatment
with hypofractionated helical tomotherapy with a curative
aim, 3) a follow-up period of 4 months, 4) at least 2
laboratory studies within 4 months of completing helical
tomotherapy, 5) at least 2 radiologic study within 4 months
of completing helical tomotherapy, and 6) no intrahepatic
disease progression within 4 months of completing
helical tomotherapy.
Between March 2006 and February 2012, a total of 98
patients were found to meet these inclusion criteria.
All of the patients received hypofractionated RT using
TomoTherapy Hi-Art (TomoTherapy, Madison, WI, USA)
at Seoul St. Mary’s Hospital and Incheon St. Mary’s
Hospital, the Catholic University of Korea. Of those, 66
patients received 45–50 Gy in 4.5-5 Gy fractions
(Group A) and 32 patients received 36–60 Gy in 2.5-3 Gy
fractions (Group B). The patients’ clinical and dosimetric
data were retrospectively collected following Institutional
Review Board approval (IRB of Incheon St. Mary's
Hospital, the Catholic University of Korea, Reference
number: OC12RISI0062). The patients’ characteristics
are shown in Table 1.
Target volume and treatment
The gross tumor volume (GTV) was defined as that
which was enhanced in the arterial phase and diluted in
the delayed phase of the computed tomography (CT)
scan. The planning target volume (PTV) was generated
by adding 5–15 mm to the GTV in 63 of the 98 patients,
facilitating asymmetric margin expansion to reduce
irradiation to the stomach, duodenum, and small intestine.
In the remaining 35 of the 98 patients, 4-dimensional
CT (4D-CT) was performed to generate the internal
target volume to compensate for respiration-induced
liver movement because of the installation of 4D-CT inMarch 2009 at Seoul St. Mary’s hospital and in March
2011 at Incheon St. Mary’s hospital. Organs at risks
such as the total liver, non-target normal liver (NTNL),
stomach, duodenum, intestine, kidney, and spinal cord
were also contoured for evaluation of the irradiated
dose. The NTNL volume was the total liver volume
minus the PTV.
The radiation dose was 45–50 Gy in 4.5-5 Gy fractions
for Group A and 36–60 Gy in 2.5-3 Gy fractions for
Group B, prescribed to 95% of the PTV. 4.5-5 Gy per
fraction was used in smaller PTV and 2.5-3 Gy per
fraction was used in larger PTV. Prior to actual beam
delivery, megavoltage cone-beam CT was performed
during every treatment session. The patients’ set-up
and position were corrected using automated image
registration, and the anatomical accuracy was always
evaluated by a radiation oncologist.
Definition and evaluation of the radiation-induced
hepatic toxicity
RIHT was defined as an increase of at least 2 points in
the Child-Pugh score (CP score) within 4 months after
the completion of helical tomotherapy. The CP score,
which is calculated on the basis of the serum bilirubin
and albumin levels, the prothrombin time (PT), and the
presence and degree of ascites or encephalopathy, is used
as an assessment of hepatic function and an increase in the
CP score reflects a deterioration in hepatic function [13].
Patients were evaluated weekly by a physician during
the treatment and followed up every 1–2 months after
the completion of treatment. At every visit, physical
examinations and blood tests were performed to assess
hepatic toxicity. The levels of aspartate transaminase
(AST), alanine transaminase (ALT), alkaline phosphatase
(ALP), serum albumin, total bilirubin and the PT were
examined and we also checked the presence of ascites
and hepatic encephalopathy.
Determination of the α/β ratio for the normal liver
We attempted to identify the statistically significant
parameters in the 2 groups using an α/β ratio of 2, 4, 6, 8,
or 10, and compared the estimated probability curves of
each significant parameter (Figure 1A, 1B). We hypothe-
sized that if the α/β ratio resulting in the best match for
curves of each parameter between 2 groups would be
equivalent to the α/β ratio of the normal liver (Figure 1C).
The dose-volumetric values were calculated on the
basis of dose-volumetric histograms (DVH) and converted
to the BED according to the linear quadratic model
(assuming an α/β ratio of 2, 4, 6, 8, or 10, respectively)
in all patients. The dose-volumetric parameters for
predicting RIHT were the percentage of the NTNL volume
receiving more than a BED of 5 Gy (VBED5), more than a
BED of 10 Gy (VBED10), more than a BED of 15 Gy
Table 1 Clinical characteristics of patients in Group A and
Group B
Characteristics
Group A (n = 66) Group B (n = 32) p
valuen % n %
Gender 0.147
Male 52 78.8 29 90.6





0 22 33.3 10 31.3
1 44 66.7 21 65.6
2 0 0 1 3.1
Hepatitis 0.484
HBV 47 71.2 24 75.0
HCV 6 9.1 2 6.3
Others 13 19.7 6 18.9
Liver cirrhosis 0.279
No 14 21.2 10 31.2
Yes 52 78.8 22 68.8
PVTT 0.677
No 28 42.4 15 46.9
Yes 38 57.6 17 53.1
AFP (IU/mL) 0.190
<400 45 68.2 18 56.3
≥400 21 31.8 14 43.7
Child-Pugh class 0.059
A 49 74.2 29 90.6
B 17 25.8 3 9.4
AJCC stage 0.741
II 12 18.2 4 12.5
III 47 71.2 25 78.1
IV 7 10.6 3 9.4
Previous treatment 0.964
No 7 10.6 3 9.4
Yes 59 89.4 29 90.6
TACE 58 87.9 28 87.5
RFA 7 10.6 2 6.3
PEI 7 10.6 3 9.4
Surgery 9 13.6 7 21.9
Treatment after RT 0.180
No 31 47.0 10 31.3
Yes 35 53.0 22 68.8
TACE 35 53.0 22 68.8
RFA 2 3.0 0 0
Table 1 Clinical characteristics of patients in Group A and
Group B (Continued)
PEI 2 3.0 1 3.1
Systemic CTx 3 4.5 3 9.4
Abbreviations: ECOG PS = Eastern Cooperative Oncology Group performance
status; HBV = hepatitis B virus; HCV = hepatitis C virus; PVTT = portal vein tumor
thrombosis; AFP = alpha-fetoprotein; AJCC = American Joint Committee on
Cancer; TACE = transcatheter arterial chemoembolization; RFA = radiofrequency
ablation; PEI = percutaneous ethanol injection; RT = radiotherapy;
CTx = chemotherapy.
Son et al. Radiation Oncology 2013, 8:61 Page 3 of 8
http://www.ro-journal.com/content/8/1/61(VBED15), more than a BED of 20 Gy (VBED20), more than a
BED of 25 Gy (VBED25), more than a BED of 30 Gy
(VBED30), more than a BED of 35 Gy (VBED35), more than a
BED of 40 Gy (VBED40), more than a BED of 45 Gy (VBED45)
and more than a BED of 50 Gy (VBED50).
Using logistic regression models and receiver operating
characteristic (ROC) curves, statistically significant
parameters were identified in each group using an α/β
ratio of 2, 4, 6, 8, or 10. The values of the area under
the curve (AUC) were obtained for each α/β ratio
group and each treatment group (Group A and Group B).
We then compared the estimated probability curve of
each significant parameter between Group A and Group B
to determine the α/β ratio that resulted in the best match
between the 2 curves.
Statistical analysis
Pearson’s chi-square test and the independent t-test were
used to compare the clinical characteristics between the
2 groups (Group A vs. Group B). Binary logistic analysis
was used for univariate analysis of dose-volumetric
parameters associated with RIHT. Multivariate analysis
involved stepwise procedures containing all significant
variables according to the univariate analysis, and the
ROC curve was used to evaluate the significant dosimetric
parameters. Statistical analysis was performed using SPSS
ver. 12.0 (SPSS Institute, Chicago, Illinois) and a p value of
<0.05 was considered to be significant.
Results
A total of 98 patients were enrolled in this study. 66
patients received a daily fraction size of 4.5-5 Gy
(Group A) and 32 patients received a daily fraction size of
2.5-3 Gy (Group B). There was no statistically significant
difference between the 2 groups in terms of gender,
age, Eastern Cooperative Oncology Group performance
status (ECOG PS), pretreatment CP class, American
Joint Committee on Cancer (AJCC) stage, the level of
alpha-fetoprotein (AFP), the presence or absence of
hepatitis, liver cirrhosis and portal vein tumor throm-
bosis (PVTT), prior treatment and treatment after RT
(Table 1). The PTV for Group A and Group B were
134 ± 129 cm3 (mean ± standard deviation) and 382 ±
396 cm3, respectively, and the volume of the NTNL
Figure 1 A schematic explanation of our hypothesis. (A, B) The estimated probability curves of statistically significant parameters in both
groups using different fraction sizes. (C) The α/β ratio resulting in the best match for 2 curves between the groups will be equivalent to the α/β
ratio for the normal liver.
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1184 ± 302 cm3, respectively.
After the completion of helical tomotherapy, RIHT
developed in 43 (43.9%) of 98 patients: 28 patients (42.4%)
in Group A and 15 patients (46.9%) in Group B. The
results of multivariate analysis evaluating the association
between dose-volumetric parameters and RIHT in each
treatment group using an α/β ratio of 2, 4, 6, 8, or 10, are
summarized in Table 2. When an α/β ratio of 2 or 4 was
used, different parameters were statistically significant in
multivariate analysis (Group A: VBED30 for α/β ratio = 2
and VBED25 for α/β ratio = 4, Group B: VBED25 for α/β
ratio = 2 and VBED20 for α/β ratio = 4). Therefore, we
compared the same parameters in each group using an
α/β ratio of 2 or 4 (VBED25 and VBED30 for α/β ratio = 2
and VBED20 and VBED25 for α/β ratio = 4). When an α/β
ratio of 6, 8, or 10 was used, VBED20 was a statistically
significant parameter in both groups. In addition, theseparameters were verified using the ROC curve and the
values of AUC. These results are shown in Figure 2 and
Table 2. The AUC values in group A and Group B were
more than 0.861 and 0.914, respectively, which were
statistically significant (p < 0.001).
Next, we compared the estimated probability curve of
each significant parameter between the 2 groups to
determine the α/β ratio for normal liver. According to
the data in Figure 3, the estimated probability curves of
significant parameters showed the closest match between
the 2 groups using an α/β ratio of 8. Therefore, we suggest
that the α/β ratio for the normal liver with hepatitis is 8.
Discussion
RT has not been generally used for the treatment of
HCC because of the low tolerable dose of radiation for
whole liver, which is insufficient to achieve tumor control
[14-16]. However, several studies have recently reported
Table 2 The significant parameters and the values of AUC associated with an increase in CP score in both groups
according to α/β ratio of 2, 4, 6, 8, or 10
Group A Group B
Significant parameter p value AUC p value Significant parameter p value AUC p value
†α/β = 2
VBED25 <0.001 0.859 <0.001 *VBED25 0.002 0.914 <0.001
*VBED30 <0.001 0.863 <0.001 VBED30 0.003 0.914 <0.001
†α/β = 4
VBED20 <0.001 0.859 <0.001 *VBED20 0.002 0.922 <0.001
*VBED25 <0.001 0.864 <0.001 VBED25 0.003 0.914 <0.001
α/β = 6 VBED20 <0.001 0.864 <0.001 VBED20 0.002 0.933 <0.001
α/β = 8 VBED20 <0.001 0.861 <0.001 VBED20 0.002 0.933 <0.001
α/β = 10 VBED20 <0.001 0.866 <0.001 VBED20 0.002 0.933 <0.001
*most significant parameter.
† When an α/β ratio of 2 or 4 was used, different parameters were statistically significant in multivariate analysis (Group A: VBED30 for α/β ratio = 2 and VBED25 for
α/β ratio = 4, Group B: VBED25 for α/β ratio = 2 and VBED20 for α/β ratio = 4). Therefore, we compared same parameters in each group using an α/β ratio of 2 or 4
(VBED25 and VBED30 for α/β ratio = 2 and VBED20 and VBED25 for α/β ratio = 4).
Abbreviation: AUC = area under the curve.
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a useful tool for the treatment of HCC within acceptable
toxicity ranges [17-19]. Furthermore, the emergence of
3-dimensional treatment planning systems has enabled
the collection of quantitative information regarding the
dose-volume relationship in regions of interest, leading
several investigators to report predictive parameters for
RIHT [2-11]. These parameters and their values have
helped to determine the appropriate radiation dose to
be use in RT.
RIHT is a significant dose-limiting toxicity for RT in
patients with HCC. Radiation-induced liver disease
(RILD) is a well-established concept of hepatic toxicity
[16], and previously, classic RILD was a serious hepatic
toxicity caused by irradiation of 30–35 Gy to the entire
liver. However, the incidence of classic RILD has decreasedFigure 2 The ROC curves and derived AUC values for statistically sign
both groups using an α/β ratio of 2, 4, 6, 8, or 10.after partial volume irradiation came into general use [5,6].
Other authors reported the parameters predicting the
non-classic RILD; for example, the elevation of hepatic
enzymes ≥ grade 2 or 3 as defined by Radiation Therapy
Oncology Group (RTOG) toxicity criteria or Common
Terminology Criteria for Adverse Events (CTCAE) or
the progression of CP class [2,5-8]. Although RIHT has
been evaluated according to various different criteria,
dose-volumetric parameters and their cut-off values
resulting from these studies have been used as guidelines
for radiation planning in the treatment of HCC.
There is some uncertainty when using different fraction
sizes for treatment. Although an α/β ratio of 10 could be
used to calculate the BED delivered to the tumor, the BED
delivered to the normal liver could not be calculated as
the α/β ratio for the normal liver was unknown. In spiteificant parameters associated with an increase in the CP score in
Figure 3 Comparison of the estimated probability curve of each significant parameter between groups to determine the α/β ratio for
the normal liver.
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with respect to various different criteria of hepatic toxicity
in previous studies. To calculate the BED delivered to the
normal liver, Cheng et al. used an α/β ratio of 2 for grade
3 or worse CTCAE hepatic toxicity [10], and Dawson et al.
used an α/β ratio of 2 or 2.5 for cases of classic RILD [3,9].
Kim et al. used an α/β ratio of 10 to calculate the BED for
cases of grade 2 or worse CTCAE hepatic toxicity [2], and
Liang et al. did not calculate the BED for classic RILD as
there was no clear α/β ratio for the normal liver [4,5].
For these reasons, it is important to determine the α/β
ratio for the normal liver. Here, we have attempted to
determine the α/β ratio for the normal liver indirectly
on the basis of the toxicity data from 2 patient groups
treated with different fraction sizes.
We defined RIHT as an increase of at least 2 points in
the CP score. In our previous study, the progression of
CP class was analyzed as a useful radiation dose-limitingtoxicity, whereas the elevation of hepatic enzymes
according to the CTCAE scale was not appropriate in
these circumstance [6]. Liaw et al. also used an increase
of at least 2 points in the CP score to evaluate the
deterioration of hepatic function in patients who were
treated with lamivudine [13]. The CP score is an assess-
ment tool to examine the severity of hepatic functional
impairment, and the increase in the CP score reflects the
deterioration in the hepatic function. Therefore, we believe
that an increase in the CP score corresponds to the
dose-limiting hepatic toxicity for the patients with HCC.
We analyzed the hepatic toxicities that occurred
within 4 months of treatment. Classic RILD typically
occurs 4–8 weeks after the completion of RT, although
it has been reported to occur as early as 2 weeks and
as late as 7 months [20]. According to Dawson et al.
and Liang et al., it occurred within 4 months after the
completion of RT [3,5]. Kim et al. and Cheng et al.
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occurred within 3 or 4 months [2,10]. Therefore, we
considered a 4 month follow-up duration to be reasonable
in this study.
In this study, 4.5-5 Gy per fraction was used in Group
A and 2.5-3 Gy per fraction was used in Group B; The
difference in fraction size between the 2 groups was thus
2 Gy. Although the fact that the same fraction size was
not used for treatment was considered a weak point, the
maximal difference in groups was only 0.5 Gy and it did
not affect our analysis because the dose-volumetric
values were converted to the BED according to the linear
quadratic model (assuming α/β ratio of 2, 4, 6, 8, or 10) in
all patients.
The results of our study suggest that the α/β ratio for
the normal liver in the patients with HCC was 8, but
there are a few points to be considered when accepting
our result. First, the α/β ratio is derived from toxicity
data when defining the RIHT as an increase of at least 2
points in the CP score. Whether our result could be
applied equally when estimating classic RILD or non-
classic RILD, such as RTOG or CTCAE hepatic toxicity
grade, will need to be tested in further study. Because
CTCAE grade was not an appropriate measure of
dose-limiting hepatic toxicity, and classic RILD was
not significant because of its rare incidence in our
previous study, these types of toxicities were therefore
not analyzed in this study [6]. Second, all the patients
received helical tomotherapy. Because radiation is
delivered continuously from all angles around the patient
via a ring gantry, a much wider region of normal liver was
irradiated with a low dose of radiation when compared to
3-dimensional conformal therapy. Our analysis showed
the most significant parameters were VBED20, VBED25 and
VBED30, which were a lower level of dose-volumetric
parameters than those of previous studies. This result
reflects that it is due to the characteristic of the planning
and delivery method of helical tomotherapy. Finally, all
patients in this study had hepatitis (Table 1). The majority
of patients with HCC also have hepatitis in eastern
countries, and thus the liver is generally less tolerant of
radiation [12]. According to Dawson et al., the mean
liver dose associated with a risk of RILD was higher for
liver metastases than for primary HCC [3]. Therefore,
when treating the metastatic liver tumors, an α/β ratio
of 8 should be used with caution if used to calculate
the BED for estimating RIHT.
Our study had some limitations. First, it was a retro-
spective study. Although there were no statistically sig-
nificant differences between the 2 groups, confounding
factors such as a selection bias might exist. Second,
small number of patients were eligible for this study
(66 patients in Group A and 32 patients in Group B).
However, the analysis results were still reliable becausethe AUC values of statistically significant parameters
were more than 0.859 and 0.914, respectively.
Conclusion
We suggest that the α/β ratio for the normal liver with
hepatitis is 8. We hope that previous reported parameters
and their values can be effectively used in different
fractionation schemes by calculating the BED using
this α/β ratio, and we hope for further confirmation in
larger-scale studies.
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